Plavix Tablet, Film Coated
Product Images NDC 0024-1332

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 0024-1332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Plavix 01)

Chemical structure of clopidogrel illustrating the molecular components including a thiophene ring, a piperidine ring, a chlorophenyl group, and a methyl ester function, associated with sulfuric acid (H2SO4). This structure corresponds to the active ingredient in Plavix tablets.*

FDA Label Image

Figure (Plavix 02)

A horizontal bar plot titled 'Effect on active metabolite AUC Mean and 90% confidence interval' showing the impact of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg relative to Plavix administered alone. The x-axis represents the change relative to Plavix alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure (Plavix 03)

A line graph depicting the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. The graph compares two groups: one receiving Plavix (clopidogrel) plus aspirin and another receiving placebo plus aspirin. The Plavix group shows a consistently lower cumulative event rate compared to the placebo group throughout the follow-up period.*

FDA Label Image

Figure (Plavix 04)

A subgroup analysis chart showing hazard ratios with 95% confidence intervals comparing Plavix (clopidogrel) to placebo across various patient subgroups. The chart is divided into two sections with different variables, including age, gender, race, diabetes, prior medical conditions, and concomitant therapies. Each subgroup includes number of patients (N) and event percentages for Plavix and placebo, with forest plots indicating whether the data favors Plavix or placebo.*

FDA Label Image

Figure (Plavix 05)

A line graph comparing the percentage of deaths before first discharge over 28 days in patients treated with clopidogrel versus placebo. The x-axis shows days since randomization (up to 28), and the y-axis shows percent dead before discharge. The graph shows fewer deaths with clopidogrel (7.5%) than placebo (8.1%), indicating a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure (Plavix 06)

A Kaplan-Meier survival curve chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph compares placebo versus clopidogrel, with annotations indicating event counts and a 9% proportional risk reduction for clopidogrel versus placebo.*

FDA Label Image

Figure (Plavix 07)

A forest plot chart depicting odds ratios with 99% confidence intervals comparing Plavix (clopidogrel) and placebo across various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent given, with an overall summary at the bottom.*

FDA Label Image

Figure (Plavix 08)

A forest plot showing a comparison of Plavix versus aspirin across different qualifying conditions (Stroke, MI, PAD) and overall, depicting hazard ratios with 95% confidence intervals indicating favorability towards Plavix or aspirin.*

FDA Label Image

Figure (Plavix 09)

A line graph depicting cumulative event rates (%) of fatal or non-fatal vascular events over months of follow-up. Two lines compare aspirin and Plavix, showing event rates increasing over time with Plavix trending slightly lower. The x-axis measures months of follow-up, and the y-axis shows cumulative event rate percentage, with a statistical significance p-value of 0.045 noted.*

FDA Label Image

Principal Display Panel (75 mg Tablet Bottle Label)

Label for Plavix 75 mg film-coated tablets by Sanofi-Aventis U.S. LLC. The label includes the product name with generic name clopidogrel, strength of 75 mg, a notation to dispense with medication guide, and a package count of 90 tablets. The label features a barcode, NDC 0024-1171-90, and storage instructions.*

FDA Label Image

Principal Display Panel (300 mg Tablet Blister Pack Carton)

Plavix 300 mg (clopidogrel tablets) film-coated oral tablets packaging label. The carton features the brand name Plavix prominently with strength 300 mg and mentions dispensing with a Medication Guide. It contains 30 tablets. Labeler Sanofi-Aventis U.S. LLC is identified along with storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.